Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 05, 2025, titled "Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma".
Press Release May 05 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
This designation aims to expedite the development and review of drugs addressing serious conditions and unmet medical needs. The drug is designed to enhance tumor targeting while minimizing toxicity, addressing a significant unmet need in multiple myeloma treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release Apr 16 2025
- Press Release Apr 01 2025
- Press Release Mar 20 2025
- Press Release Mar 12 2025
- Press Release Mar 10 2025
Later from Glenmark Pharmaceuticals
- Press Release May 23 2025
- Press Release Jun 02 2025
- Press Release Jun 09 2025
- Press Release Jun 24 2025
- Glenmark Launches a Transformative Nutrition and Livelihood Project in Emali, Kenya
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals